Abstract
CAR-T cell therapy shows revolutionary promises in the therapeutic treatment of cancer, offering the possibility of long-lasting remissions and potential cures for certain cancers. The principle of this immunotherapy is to improve patient's own T cells. It shows clinically significant efficacy in difficult-to-treat cancers. However, when overcoming solid tumors, this therapy encounters limitations of tumor infiltration, the multiple limitations of the tumor microenvironment, and the toxicity produced by CAR-T cells themselves. All these factors make the efficacy of CAR-T cell immunotherapy significantly reduced. The investigation of the causes leading to these issues is a central focus of research. The focus of this paper is on the accomplishments made in CAR-T cell therapy and the drugs that are currently available on the market. It will also cover current shortcomings of this immunotherapy and difficulties that need to be overcome. The paper will also cover a vision and prediction of future CAR-T cell therapy technology.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
